New Era of Preventing End-Stage Kidney Disease Act
Official title: To amend the Public Health Service Act with respect to preventing end-stage kidney disease, and for other purposes.
More subjectsShow fewer subjects
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
New Era of Preventing End-Stage Kidney Disease Act
This bill establishes regional centers of excellence, postgraduate fellowships, and training for health professionals relating to the diagnosis and treatment of rare kidney disease. It also requires the Department of Health and Human Services (HHS) to conduct various studies on rare kidney disease.
Specifically, it authorizes the National Institute of Diabetes and Digestive and Kidney Diseases to award funding to public and private nonprofit entities for establishing regional centers of excellence that will increase public awareness, conduct research, and develop resources for diagnosing and treating rare kidney diseases. A center may receive such funding for up to five years, unless extended by the institute.
The bill also requires health professions schools receiving a grant from the Health Resources and Services Administration (HRSA) Centers of Excellence program to award fellowships for training on preventing, diagnosing, and treating rare kidney disease in disproportionately impacted populations.
Also, the bill expands the priorities of HRSA’s Primary Care Training and Enhancement program to include training for health care workers to care for individuals with kidney disease.
Additionally, HHS must conduct several studies and report to Congress on topics such as treating rare kidney disease in disproportionately affected populations, eliminating the need for dialysis or kidney transplants, and increasing public awareness of rare kidney disease.
- Introduced in House Formatted Text PDF Formatted XML
- ALSTON & BIRD LLP
- AMERICAN KIDNEY FUND
- TIBER CREEK GROUP
- TRAVERE THERAPEUTICS
- VERTEX PHARMACEUTICALS INCORPORATED
- OTSUKA AMERICA PHARMACEUTICAL, INC.
Bodies those filers lobbied
- HOUSE OF REPRESENTATIVES
- SENATE
- Centers For Medicare and Medicaid Services (CMS)
- Health & Human Services, Dept of (HHS)
- Food & Drug Administration (FDA)
- Office of Management & Budget (OMB)
- Health Resources & Services Administration (HRSA)
- Natl Institutes of Health (NIH)
Cite this page
U.S. Congress. (2026). H.R. 1518: New Era of Preventing End-Stage Kidney Disease Act. 119th Congress. Open America. https://openamerica.io/bill/119-HR-1518/
"H.R. 1518: New Era of Preventing End-Stage Kidney Disease Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-1518/.
H.R. 1518, 119th Cong. (2026), https://openamerica.io/bill/119-HR-1518/.
[H.R. 1518: New Era of Preventing End-Stage Kidney Disease Act](https://openamerica.io/bill/119-HR-1518/)